• Y-27632 in Kidney Organoid Ciliopathy Research

  2026-08-31

  Explore how the ROCK inhibitor Y-27632 can be positioned in kidney organoid experiments without confusing cytoskeletal effects with correction of WDR19-associated ciliary defects. This article translates a recent mechanistic study into assay-design decisions, controls, and interpretation strategies.

• Ciclesonide Workflows for Respiratory Research

  2026-08-31

  Build cleaner respiratory inflammation assays by separating ciclesonide activation from downstream glucocorticoid signaling. This guide also explains how to use ciclesonide as a mechanistic comparator when evaluating the newer ERAD-hijacking approach for membrane-protein degradation.

• Quercetin, Hippo Signaling, and Cataract Protection

  2026-08-30

  A 2025 study links quercetin-mediated protection of cataractous lenses to suppression of Hippo signaling, improved redox balance, and enhanced lens epithelial-cell survival. Its combination of network pharmacology, UVB-induced cataract models, oxidative injury assays, and α-hederin reversal experiments provides a useful framework for evaluating pathway involvement while leaving important questions about direct molecular targets and clinical translation unresolved.

• Ciclesonide: Prodrug Biology for Better Assays

  2026-08-29

  Ciclesonide is a lung-activated glucocorticoid prodrug with distinctive pharmacology for asthma treatment research. This article connects its activation and assay design requirements with the ERAD-hijacking findings of Song et al., while clearly separating established evidence from forward-looking applications.

• Caspofungin Workflows for Resistant Candida Research

  2026-08-29

  Caspofungin provides a practical benchmark for studying fungal cell wall biosynthesis inhibition, susceptibility shifts, and delayed-treatment efficacy in Candida models. This workflow-centered guide connects broth microdilution, time-kill testing, and translational in vivo comparisons while highlighting controls that reduce assay variability.

• Ciclesonide: Prodrug Precision for Translational Research

  2026-08-28

  Ciclesonide offers a rigorously defined prodrug-to-active-metabolite system for respiratory research, while the emerging ERAD-degrader field provides a useful strategic lens for designing better mechanistic experiments without conflating validated glucocorticoid biology with unproven degradation activity.

• Triamcinolone (B1859): Practical Research Guide

  2026-08-28

  Triamcinolone (B1859) is a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid signaling, inflammation, and immunosuppression. This guide addresses solvent selection, preparation, storage, controls, and troubleshooting; the compound is for scientific research only and should not be used for diagnostic, therapeutic, or clinical purposes.

• Hoechst 33342/PI Double Staining Kit Guide

  2026-08-27

  The Hoechst 33342/PI Double Staining Kit (K2237) provides a two-color research workflow for comparing nuclear chromatin condensation with loss of cell membrane integrity. It is suitable for fluorescence microscopy-based apoptosis and necrosis studies, but it is not validated for diagnostic, clinical, or medical use.

• 2-Hydroxypropyl-β-cyclodextrin Protocol Guide

  2026-08-27

  2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen and improve the aqueous handling of poorly soluble hydrophobic compounds, particularly compounds containing aromatic or phenyl groups. This guide supports pharmaceutical and biochemical solubility workflows, but it does not establish compound-specific efficacy, therapeutic performance, or bioavailability outcomes.

• Ciclesonide Workflows for Translational Lung Research

  2026-08-26

  Ciclesonide offers a practical way to model tissue-relevant glucocorticoid activation, linking parent-drug exposure with formation of the far more potent desisobutyryl-ciclesonide. This guide converts that biology into reproducible cell, pharmacology, and translational workflows while clearly separating established respiratory evidence from emerging ERAD concepts.

• Thermal-Protective Hydrogel for Tumor Ablation

  2026-08-26

  The reference study develops an injectable MR@CaP@HA hydrogel that combines local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. Its integrated design protects nearby tissue, strengthens immunogenic cell death and innate immune response modulation, and produced complete tumor eradication in a subset of treated animals.

• Sorafenib (BAY-43-9006) Research Workflow

  2026-08-25

  Build reproducible cancer experiments with Sorafenib as a pathway and angiogenesis perturbation tool, then pair kinase readouts with mitochondrial cholesterol and mitophagy assays. The workflow separates direct tumor proliferation inhibition from broader metabolic effects in hepatocellular carcinoma models.

• ATRX Loss Sensitizes Glioma to RTK Inhibitors

  2026-08-25

  The reference study shows that ATRX-deficient high-grade glioma cells are more vulnerable to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient controls. Its combination data further suggest that pairing these inhibitors with Temozolomide may expose a therapeutically relevant vulnerability, supporting ATRX status as a biomarker for glioma research and clinical-trial interpretation.

• Rifampin Workflows for Transcription Control

  2026-08-24

  Rifampin provides a rapid, chemical way to interrogate bacterial transcription, resistance, and RNA turnover without redesigning a genetic circuit. This guide pairs practical Rifampin workflows with the translational-control concepts emerging from a light-inducible gene-switch study.

• Dynamic Myelin Remodeling After CNS Damage

  2026-08-23

  Arafa and colleagues show that early CNS myelin damage is often marked by swelling, but swelling does not inevitably result in sheath loss. Cross-species live imaging and activity-manipulation experiments indicate that neuronal activity can worsen early pathology, while some damaged sheaths remodel and partially recover.

450 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page